NCT04512053View on ClinicalTrials.gov

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

PHASE2CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions
Stress Urinary Incontinence
Interventions
DRUG

TAS-303 18 mg/day

Oral administration for 12 weeks, once daily

DRUG

Placebo

Oral administration for 12 weeks, once daily

Trial Locations (4)

Unknown

A site selected by Taiho Pharmaceutical Co., Ltd., Aichi

A site selected by Taiho Pharmaceutical Co., Ltd., Fukuoka

A site selected by Taiho Pharmaceutical Co., Ltd., Osaka

A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence | Biotech Hunter | Biotech Hunter